Slentrol
dirlotapide
Table of contents
Overview
The marketing authorisation for Slentrol has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Slentrol
|
| Agency product number |
EMEA/V/C/000116
|
| Active substance |
dirlotapide
|
| International non-proprietary name (INN) or common name |
dirlotapide
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QA08AB91
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Zoetis Belgium SA
|
| Revision |
7
|
| Date of issue of marketing authorisation valid throughout the European Union |
13/04/2007
|
| Contact address |
Rue Laid Burniat 1 |
Product information
15/01/2015 Slentrol - EMEA/V/C/000116 - IAIN/0007/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiobesity preparations, excl. diet products
Therapeutic indication
As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight-management programme that also includes appropriate dietary changes and exercise practice.